1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders
Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, R a , R 1 , R 2 , R 3 , R 4 , R 6 , w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.
1. A process for preparing a compound of formula
or a pharmaceutically acceptable salt thereof, comprising:
a) combining
with an acid to form
b) separating
into
and
c) isolating
2. The process according to claim 1 further comprising forming
by mixing
and a base and isolating
3. The process according to claim 2 further comprising forming
by mixing
with methanesulfonyl chloride and isolating
4. The process according to claim 3 further comprising forming
by mixing
with F and isolating
5. The process according to claim 4 further comprising forming
by reacting
with
and isolating
6. The process according to claim 5 further comprising forming
by mixing
with TBDMSCl and isolating
7. A process for preparing a compound of formula
or a pharmaceutically acceptable salt thereof, comprising:
a) combining
with an acid to form
b) separating
into
and
c) isolating
8. The process according to claim 7 further comprising forming
by mixing
and a base and isolating
9. The process according to claim 8 further comprising forming
by mixing
with methanesulfonyl chloride and isolating
10. The process according to claim 9 further comprising forming
by mixing
with F − and isolating
11. The process according to claim 10 further comprising forming
by reacting
with
and isolating
12. The process according to claim 11 further comprising forming
by mixing
with TBDMSCl and isolating
13. A process for preparing a compound of formula
or a pharmaceutically acceptable salt thereof, comprising:
a) combining
with an acid to form
b) separating
into
and
c) isolating
14. The process according to claim 13 further comprising forming
by mixing
and a base and isolating
15. The process according to claim 14 further comprising forming
by mixing
with methanesulfonyl chloride and isolating
16. The process according to claim 15 further comprising forming
by mixing
with F − and isolating
17. The process according to claim 16 further comprising forming
by reacting
with
and isolating
18. The process according to claim 17 further comprising forming
by mixing
with TBDMSCl and isolating
19. A process for preparing a compound of formula
or a pharmaceutically acceptable salt thereof, comprising:
a) combining
with an acid to form
b) separating
into
and
c) isolating
20. The process according to claim 19 further comprising forming
by mixing
and a base and isolating
21. The process according to claim 20 further comprising forming
by mixing
with methanesulfonyl chloride and isolating
22. The process according to claim 21 further comprising forming
by mixing
with F − and isolating
23. The process according to claim 22 further comprising forming
by reacting
with
and isolating
24. The process according to claim 23 further comprising forming
by mixing
with TBDMSCl and isolating